Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24733063 | 0.89 | ACP1 (0.45) | ACP1RAB9ATLR7SIGMAR1MAPT | |
| SCHEMBL29809309 | 0.89 | ACP1 (0.45) | ACP1RAB9ATLR7SIGMAR1MAPT | |
| SCHEMBL29809097 | 0.88 | FABP4 (0.44) | ACP1RAB9ATLR7SIGMAR1MAPT | |
| SCHEMBL29977565 | 0.88 | ACP1 (0.44) | ACP1RAB9ATLR7SIGMAR1HTR1A | |
| SCHEMBL24733118 | 0.88 | FABP4 (0.44) | ACP1RAB9ATLR7SIGMAR1MAPT | |
| SCHEMBL29808964 | 0.86 | ACP1 (0.45) | ACP1TLR7SIGMAR1MAPTSSTR5 | |
| SCHEMBL24733512 | 0.86 | ACP1 (0.45) | ACP1TLR7SIGMAR1MAPTSSTR5 | |
| SCHEMBL27213644 | 0.86 | TLR7 (0.47) | ACP1RAB9ATLR7SIGMAR1HTR1A | |
| SCHEMBL28802673 | 0.86 | TLR7 (0.47) | ACP1TLR7SIGMAR1MAPTBCHE | |
| SCHEMBL24732883 | 0.85 | TLR7 (0.46) | ACP1TLR7BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | ACP1 3773/4885RAB9A 2034/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.